Seborrheic dermatitis Seborrheic dermatitis, laser, microbiome, proteomics
Conditions
Interventions
Participants with facial seborrheic dermatitis will receive treatment with a 1726-nm laser, administered in three sessions at one-month intervals. Clinical evaluations will be performed at baseline an
Experimental Device,No Intervention No treatment
1726 nm laser (22 cases),Control (10 cases)
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Thai male or female participants aged 25 to 50 years. 2. Diagnosis of facial seborrheic dermatitis of moderate to severe severity, as assessed by a dermatologist using the Seborrheic Dermatitis Area and Severity Index (SEDASI). 3. Participants of Asian ethnicity (Thai).
Exclusion criteria
Exclusion criteria: 1. Pregnant women, women within 1 year postpartum, or breastfeeding women. 2. Individuals who do not provide written informed consent to participate in the study. 3. History of Cushing syndrome or Ehlers Danlos syndrome. 4. Use of antibiotic or antifungal treatments for facial seborrheic dermatitis, including oral or topical formulations or any other treatment modalities, within 1 month prior to study enrollment. 5. Use of oral isotretinoin within 1 year prior to study enrollment. 6. History of chemical peeling procedures within 1 month prior to study enrollment. 7. History of malignancy, ongoing cancer treatment, or skin cancer at the treatment site. 8. History of immunodeficiency, including HIV infection or AIDS. 9. History of keloid formation or other dermatologic conditions at the treatment site. 10. Presence of open wounds or active skin infections at the treatment site. 11. History of herpes simplex infection or current active herpes infection. 12. History of psychiatric disorders. 13. Any medical condition that, in the investigators judgment, may compromise participant safety or interfere with study participation. 14. Refusal to allow clinical photography for treatment outcome assessment. 15. Receipt of the following medications within 6 months prior to sample collection: a. Systemic antibiotics, antifungals, antivirals, or antiparasitic agents (intravenous or intramuscular). b. Systemic corticosteroids (intravenous or intramuscular). c. Cytokine therapies (intravenous or intramuscular). d. High-dose commercial probiotics in the form of tablets, capsules, lozenges, chewing gum, or powders containing probiotics as the main component (fermented foods such as yogurt or fermented milk products are permitted). 16. Use of oral antibiotics, antifungals, antivirals, or antiparasitic agents within 6 weeks prior to sample collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes on the skin microbiome at the facial and lesional sites using skin swabbing before and after being treated with the 1726-nm laser baseline, 1 month after complete treatment skin swabbing,changes in global transcriptome of tape strips from seborrheic dermatitis lesion before and after being treated with the 1726-nm wavelength laser baseline, 1 month after complete treatment tape stripping,Physician assessment 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment quartile improvement scale,Safety of the 1726-nm wavelength laser in treating seborrheic dermatitis 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| Sebum level Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Sebumeter,Redness level Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Antera,Pigmentation Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Antera,Pores Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Antera,Texture of skin Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Antera,Melanin index Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Mexameter,Erythema index Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Mexameter,Quality of Life Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1-,3- and 6-month after 3rd treatment Dermatology Life Quality Index (DLQI),The differences of the bacterial composition, relative abundance, and microbial diversity among lesional, non-lesional and healthy volunteer Baseline Skin swabbing for microbiomes study,The differences of the global transcriptome of tape strips from lesional and non-lesional skin of seborrheic dermatitis patients and skin of healthy patients Baseline Skin tape stripping for proteomics study | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed